<DOC>
	<DOCNO>NCT01268527</DOCNO>
	<brief_summary>The purpose study investigate efficacy , safety , tolerability concentration/response relationship E6201 subject psoriasis vulgaris .</brief_summary>
	<brief_title>A 12-Day Randomized , Blinded , Vehicle Active Comparator-Controlled Study Determine Efficacy Safety Six Concentrations Topical E6201 Gel Subjects With Psoriasis Vulgaris</brief_title>
	<detailed_description>This single center , randomize , blind , intra-individual comparison two sequential cohort 15 subject ( 30 subject total ) outpatient setting , subject simultaneously receive five topical treatment ( 3 active , 1 vehicle , 1 positive control ) within one two psoriatic plaque . Treatments consist 3 concentration E6201 gel , negative control ( gel vehicle ) , positive control ( 0.005 % calcipotriene cream ) . The different concentration E6201 gel vehicle control double-blinded , calciprotriene cream single-blinded . Cohort 2 participant dose participant Cohort 1 complete treatment safety data collect evaluate .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>Inclusion : Chronic stable plaque psoriasis one two stable psoriatic plaque ( ) suitable size location five separate treatment field assess within . Males female age 18 75 year age The general physical examination normal ( exclude skin examination psoriasis ) unless Investigator considers abnormality clinically significant regard study Females childbearing potential must negative serum betahuman chorionic gonadotropin Visit 1 ( Screening ) negative urine pregnancy test prior start study drug ( ) ( Visit 2 ) . Female subject childbearing potential must agree abstinent use highly effective method contraception throughout study period 30 day last dose study drug . Provide write informed consent Willing able comply aspect protocol Exclusion : Any clinically significant skin diseases chronic stable plaque psoriasis Other type psoriasis chronic stable plaque variant eg , guttate , pustular , erythodermic , etc An unstable course disease define flare ( ) previous month Subjects use concommitant topical treatment psoriatic plaque ( ) study ( emollient salicylic acid ) within 8 week Baseline visit eg corticosteroid topical immunomodulators , anthralin ( dithranil ) , vitamin D derivative , ultravioletlight therapy include sunbathing , retinoids . Subjects use follow systemic treatment within 12 week Baseline visit eg : corticosteroid adrenocorticotrophic hormone analog , retinoids acitretin isotretinoin , cyclosporin , interferon , methotrexate , immunosuppressive/immunomodulating drug , psoralen ultraviolet A therapy , biologics Subjects plan significant exposure sun ( sunbathe ) Treatment systemic locally act medication might counter influence study aim ( eg monoamine oxidase inhibitor , antiepileptic drug , antipsychotic drug ) medication know provoke aggravate psoriasis , eg Betablockers , antimalarial drug , lithium within two week Baseline visit Subject dependent person , ie , relative/family member Investigator and/or member Investigator 's staff Clinical study participation investigational drug le 30 day prior study entry plan receive investigational drug study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Psoriasis vulgaris</keyword>
</DOC>